Literature DB >> 14671815

[Drug therapy of elderly patients from the viewpoint of the clinical pharmacologist].

M Wehling1, A Peiter.   

Abstract

Polypragmasy (polypharmacotherapy) is often due to the frequent incidence of multimorbidity among elderly patients. This may evoke unpredictable drug-interactions, which often become a reason for hospitalization. Additional medications might be the consequence. Geriatric patients are often characterized by variant pharmacokinetic parameters. Individualized drug-therapy should take into consideration not only the patients' age, liver and kidney functions but also the individual variability of hepatic metabolization and drug-resorption in the intestine based on genetic polymorphisms. Summing up, it is very important to verify a consisting or a new drug-therapy concerning its risk-benefit ratio and if it is needed, to omit or change some of the medications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14671815     DOI: 10.1007/s00108-003-0950-4

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  6 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

Review 2.  Explicit criteria for determining potentially inappropriate medication use by the elderly. An update.

Authors:  M H Beers
Journal:  Arch Intern Med       Date:  1997-07-28

Review 3.  Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment.

Authors:  J Brockmöller; J Kirchheiner; C Meisel; I Roots
Journal:  Pharmacogenomics       Date:  2000-05       Impact factor: 2.533

4.  The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.

Authors:  B Greiner; M Eichelbaum; P Fritz; H P Kreichgauer; O von Richter; J Zundler; H K Kroemer
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

5.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321

6.  Increased incidence of levodopa therapy following metoclopramide use.

Authors:  J Avorn; J H Gurwitz; R L Bohn; H Mogun; M Monane; A Walker
Journal:  JAMA       Date:  1995-12-13       Impact factor: 56.272

  6 in total
  3 in total

1.  [What is the meaning of safety in hospitals?].

Authors:  D Eschmann; K Schüttpelz-Brauns; U Obertacke; U Schreiner
Journal:  Unfallchirurg       Date:  2013-10       Impact factor: 1.000

Review 2.  Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects.

Authors:  Martin Wehling
Journal:  Eur J Clin Pharmacol       Date:  2014-08-28       Impact factor: 2.953

Review 3.  [Age 70 and older a criterion for inclusion - not exclusion].

Authors:  G Glaeske
Journal:  Urologe A       Date:  2015-12       Impact factor: 0.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.